HOST Therabiomics Wants to Develop Dietary Compound into Bowel-disease Treatment

HOST Therabiomics Wants to Develop Dietary Compound into Bowel-disease Treatment
HOST Therabiomics hopes to develop the dietary compound HOST-G904, which improved the composition of gut bacteria without increasing gas, into a treatment for inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and other gut conditions. The company published a study of the investigational prebiotic’s impact on gut bacteria, “Metabolic adaptation of colonic microbiota to galactooligosaccharides: a proof-of-concept-study,” in the journal Alimentary Pharmacology

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *